Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx (Nasdaq: CDNA) announced inducement equity awards on November 4, 2025 under its 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted restricted stock units (RSUs) to 49 new employees totaling 113,250 shares and separately granted 88,180 RSUs to Dr. Jeffrey Teuteberg upon his appointment as Chief Medical Officer. The RSUs vest over four years: 25% on the first anniversary of each recipient’s vesting commencement date and thereafter 1/16th each quarter, subject to continued service.
CareDx (Nasdaq: CDNA) announced new kidney transplant molecular data and the launch of HistoMap Kidney, a tissue-based gene expression assay that complements pathology to characterize rejection phenotypes.
Key scientific presentations at ASN Kidney Week 2025 (Nov 6–8) included AlloView/AlloSure Plus performance for predicting antibody-mediated rejection, a 54-patient study finding donor kidney volume did not affect AlloSure levels or 1-year graft function, and results showing AlloSure plus blood gene expression profiling are usable for rejection screening from week 1 post-transplant. HistoMap Kidney will be available early 2026 via a clinical study.
CareDx (Nasdaq: CDNA) reported Q3 2025 revenue of $100.1M, up 21% year‑over‑year, driven by testing services revenue of $72.2M (+19%) and testing volume of ~50,300 samples (+13%). GAAP net income was $1.7M versus a GAAP loss of $10.6M in Q3 2024; adjusted EBITDA was $15.3M versus $6.9M a year earlier. Cash, cash equivalents and marketable securities totaled $194.2M as of September 30, 2025, net of a $25.6M share repurchase; no debt outstanding. The company raised full‑year 2025 revenue guidance to $372M–$376M and adjusted EBITDA guidance to $35M–$39M.
CareDx (Nasdaq: CDNA) announced the appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of clinical transplantation experience, including senior roles at Stanford and University of Pittsburgh Medical Center, board certification in Heart Failure/Cardiac Transplantation, and prior service as President of ISHLT.
He will lead CareDx’s global Medical Affairs, including Medical Directors, Medical Science Liaisons, and clinical research operations, and has served as principal investigator of the SHORE study on noninvasive rejection surveillance.
CareDx (Nasdaq: CDNA) published the second SHORE study in Journal of the American College of Cardiology: Heart Failure on October 23, 2025, reporting the largest prospective analysis of antibody-mediated rejection (AMR) in heart transplantation.
The study covered 2,240 patients across 59 U.S. centers, analysing 24,768 biopsies, 8,851 paired AlloSure Heart dd-cfDNA samples, and 136 AMR-positive biopsies paired with dd-cfDNA. AlloSure Heart ≥0.50% showed 92.8% specificity for AMR. Results supported context-dependent AlloSure thresholds to reduce unnecessary biopsies and showed AlloSure declines after presumed AMR treatment, indicating response monitoring utility.
CareDx (Nasdaq: CDNA) announced on October 22, 2025 the appointment of Suresh Gunasekaran to its Board of Directors.
Gunasekaran is president and CEO of UCSF Health, which the release notes has over $9 billion in annual revenue and 20,000 employees. He brings more than 20 years of executive leadership in healthcare administration and information technology and prior CEO and senior roles at University of Iowa Hospitals & Clinics, UT Southwestern, Healthlink/IBM, Gartner, and Vanderbilt Children’s Hospital.
CareDx highlighted Gunasekaran’s experience in clinical innovation and health system leadership and said his perspective will support the company’s efforts to advance diagnostic solutions for transplant patients.
CareDx (Nasdaq: CDNA) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. The company will host a webcast and conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. Telephone participants must register to receive a dial-in number and unique PIN.
CareDx (Nasdaq: CDNA) announced product launches and regulatory milestones at ASHI 2025 (Oct 6–10, 2025) highlighting new HLA diagnostics and European IVDR certification. Key items include the AlloSeq Tx11 launch with enhanced Class II coverage plus non‑HLA markers (ABO, CCR5, LIMS1, APOL1); a modernized SCORE 7 analysis app for QTYPE; a novel same‑day long‑read HLA assay offered via an Early Access Program; and an ABO genotyping qPCR assay that showed 100% concordance with established methods across three clinical sites. CareDx said its AlloSeq Tx and QTYPE products received IVDR certification in the EU, meeting the new regulatory standard ahead of the December 2027 deadline.
CareDx (NASDAQ:CDNA), a precision medicine company focused on transplant healthcare solutions, has submitted its comment letter responding to the draft Local Coverage Determination (LCD) regarding molecular testing for solid organ transplant rejection. The comment letter is available on the company's website, following the conclusion of the public comment period on August 31, 2025. A final LCD and stakeholder comment summary are expected to be published by CMS.
CareDx (NASDAQ:CDNA), a precision medicine company specializing in transplant healthcare solutions, has announced its participation in the upcoming Wells Fargo Healthcare Conference. The company will engage in a fireside chat presentation on September 5, 2025, at 8:00 AM ET in Boston, Massachusetts.
Investors and interested parties can access both the live and archived versions of the presentation through the "Events and Presentations" section on CareDx's investor relations website at investors.caredx.com.